Evotec looks to acquire Cyprotex | Chemical & Engineering News
Volume 94 Issue 43 | p. 12 | Concentrates
Issue Date: October 31, 2016

Evotec looks to acquire Cyprotex

Department: Business
Keywords: mergers & acquisitions, drug discovery, contract research

Evotec, a German contract drug discovery firm, has made a $68 million cash offer to acquire Cyprotex. The 17-year-old firm with headquarters in England conducts preclinical contract research in drug metabolism, pharmacokinetics, and toxicology. It employs 136 people across sites in Watertown, Mass.; Kalamazoo, Mich.; and Macclesfield and Alderley Park, England. The companies expect to complete the transaction before the end of the year.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment